Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...

Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...

Nov. 15, 2024 — From the Carnival in Rio de Janeiro to the shoulders of pirates: parrots are synonymous with color for people across the world. In a new study, scientists uncover a 'switch' in ...

The patient died four months after BEAM-101 infusion “due to respiratory failure that was determined by the investigator to ...

Researchers at New York University have devised a mathematical approach to predict the structures of crystals—a critical step in developing many medicines and electronic devices—in a matter of ...

Sickle cell patient files lawsuit against Global Blood Therapeutics, a wholly owned subsidiary of Pfizer, alleging harm from medication. The lawsuit, filed on Hardiman's behalf by the law firm ...

Pfizer is voluntarily withdrawing its sickle cell disease (SCD) therapy Oxbryta from all world markets after finding an "imbalance" in deaths in its clinical trials programme. Investigator sites ...

Pfizer, Inc. and Global Blood Therapeutics, Inc. were sued in San Francisco Superior Court where the plaintiff alleges the drug Oxbryta contributed to the onset of a vaso-occlusive crisis (VOC) as ...

This growth guidance considers the reduction of sales associated with the previously announced global withdrawal of Oxbryta. Pfizer Expects 2024 adjusted EPS of $2.75-$2.95 compared to prior ...

Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance (1) for both Revenues and Adjusted (2) diluted EPS.